Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results